An important new psoriasis medicine developed under a collaboration between Johnson & Johnson and University of Queensland (UQ) spin-out Protagonist Therapeutics has received approval for use by the United States Food and Drug Administration (FDA). The new drug, icotrokinra, will be marketed as ICOTYDE.
Protagonist was launched from UQ’s Institute for Molecular Bioscience (IMB) in 2001 to pioneer the development of new oral peptide drugs for hard-to-treat conditions. ICOTYDE was jointly discovered by Protagonist and JNJ scientists. The Protagonist team included members of Protagonist’s embedded research team at IMB.
Image: Protagonist Therapeutics founder Professor Mark Smythe.
“I believe this is a life-changing drug for people with this debilitating condition,” said Greg Bourne, the head of Protagonist’s IMB research team. “The science we undertake in Australia, and here at IMB, can transform lives around the world.”
Protagonist founder Professor Mark Smythe added, “These diseases affect millions of people around the world, and currently, most advanced treatments are through injection. But we also know 75 percent of people don’t like needles, especially children, so this oral drug brings targeted treatment and safety expectations with the gentleness and convenience of a once-daily pill.”
Professor Smythe held several executive positions at Protagonist until 2022, when he stepped down to become Chief Executive Officer of Infensa Bioscience Pty Ltd.
Medical milestone
Psoriasis is a chronic autoimmune condition causing inflamed skin patches that affects an estimated 60 - 125 million people worldwide. Millions of people suffer from moderate to severe forms that can have deep physical, social and psychological impacts.
IMB Executive Director Professor Ian Henderson said what it means for those patients is what makes the FDA approval so exciting.
“ICOTYDE offers a convenient, once-daily treatment for those living with psoriasis, and it paves the way for further research into oral therapeutics for other immune-mediated conditions,” Professor Henderson said.
“It highlights the power of collaborative research, reinforces IMB’s reputation as a powerhouse of scientific innovation and positions Australia as a global leader in next-generation therapeutics. Our researchers are accelerating innovation through industry partnerships to tackle diseases with high unmet needs, reaching global markets to improve the lives of millions worldwide.”
ICOTYDE is under additional assessment for the treatment of psoriatic arthritis and inflammatory bowel diseases.
IMB Translation Director, Professor Mark Blaskovich, said “Australia has played an important role in many important medical advancements, including cervical cancer vaccine Gardasil and the discovery that bacteria Helicobacter pylori causes ulcers. We’re very proud of the contribution the IMB made to ICOTYDE as well.”
Protagonist, headquartered in the US with additional research operations at IMB, is one of 20 companies launched by IMB, and one of more than 136 companies originating from UQ intellectual property.
Protagonist, in partnership with Takeda Pharmaceutical Company, is also seeking approval from the U.S. Food and Drug Administration for another drug, rusfertide, another drug developed from Protagonist’s peptide platform to treat polycythemia vera, a form of blood cancer.
Folks with severe plaque psoriasis often have to choose between convenient pills that don't work very well or highly effective injections that come with the hassle of needles. That trade-off may soon change. New clinical trial data suggests a once-daily pill called zasocitinib may provide the clear skin once only expected from shots.
The medicine is in the final stages of study and is not yet approved by the U.S. Food and Drug Administration (FDA).
Takeda Pharmaceuticals recently shared results from two late-stage clinical trials involving nearly 1,800 adults with moderate-to-severe plaque psoriasis across 21 countries.
The findings—presented at a meeting of the American Academy of Dermatology in Denver—showed that about 70% of participants taking the pill reached the goal of having clear or almost clear skin within 16 weeks.
Plaque psoriasis makes skin cells grow too fast, forming thick, scaly raised red patches with silvery scales. It causes itching and burning feelings on the skin during flare-ups.
The studies compared zasocitinib to a placebo and to apremilast, a widely available pill for psoriasis.
About 30% of patients on apremilast saw significant skin improvement, compared to more than double that amount with zasocitinib.
Researchers reported that zasocitinib worked with surprising speed.
Many patients noticed their skin starting to clear as early as four weeks into the treatment.
The results were lasting: Of the patients who hadclear skinat the nine-month mark, more than 90% still maintained those results after more than a year of daily use.
"Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies," said lead researcher Dr. Melinda Gooderham, a dermatologist in Ontario, Canada.
She added that these results show it is possible for a daily pill to deliver rapid, lasting relief.
No new or unexpected safety concerns were discovered during the trials. The most common side effects reported were generally mild, such as upper respiratory infections like a common cold.
About 6.5% of patients taking the drug also experienced acne, which is a known side effect of this specific class of medication, called TYK2 inhibitors.
"Our Phase III results demonstrate that highly selective TYK2 inhibition can offer many people with moderate-to-severe plaque psoriasis the potential for clear or nearly clear skin," said Dr. Chinweike Ukomadu, a senior vice president at Takeda and head of the company's gastrointestinal and inflammation areas.
Takeda plans to submit the drug to the FDA for approval within the next year.
Vitamin D and curcumin show some promise—but the evidence is mixed. Here’s what to know before adding supplements to your psoriasis treatment plan
Psoriasis is an immune-related condition that causes inflammation in the body. Because of that, many people wonder if changing what they eat—or taking certain supplements—might help. Some nutrients are known to fight inflammation, and a few have been studied in people with psoriasis. So it seems logical: If you can’t perfectly follow a Mediterranean or DASH diet, could a daily supplement help calm inflammation instead?
It’s not that simple. Supplements can be expensive, and so far, research on whether they improve psoriasis symptoms has been limited and mixed. To get clearer answers, researchers recently reviewed more than 20 clinical trials, published in Frontiers in Nutrition, that looked at popular supplements for psoriasis. Two showed the most promise—but results varied, and none worked for everyone. Here’s what to know before adding anything new to your routine.
Weighing the Evidence
The review examined seven commonly discussed supplements:
Curcumin
Fish oil
Multivitamins
Probiotics
Selenium
Vitamin D
XP-828L (whey protein extract)
Each of these has anti-inflammatory properties that could, in theory, help psoriasis.
“Omega-3 fatty acids [in fish oil] have the most acceptable data to support use in psoriasis, and oral supplements containing antioxidants such as vitamins A, C, E, and selenium may help promote anti-inflammatory pathways that counter the pro-inflammatory ones in psoriasis,” says Rosanne Paul, D.O., an assistant professor of dermatology at Case Western Reserve University in Cleveland, OH who was not one of the study’s authors.
Still, the overall evidence wasn’t strong enough to clearly recommend most of them. Multivitamins appeared to show the biggest improvement, but results differed greatly between studies, making it hard to trust the finding. XP-828L, a whey protein extract, showed some possible benefit, but it isn’t available in the U.S.
That left two supplements that stood out: vitamin D and curcumin.
Vitamin D
Vitamin D is often called the “sunshine vitamin.” It plays a role in skin cell growth, helps regulate immune cells in the skin, and reduces inflammation. It’s also used in some prescription topical psoriasis treatments. People with psoriasis are more likely to have low vitamin D levels, and sunlight exposure often improves symptoms.
When it comes to taking it in oral form, the review found that vitamin D supplements led to mild to moderate improvement in psoriasis symptoms overall. However, study results were inconsistent. “There is a small improvement in PASI [Psoriasis Area and Severity Index] scores, but because the studies are all over the place, it’s not clear if this is actually clinically significant,” says Jessica Kaffenberger, M.D., a board-certified dermatologist specializing in psoriasis at The Ohio State University Wexner Medical Center in Columbus, OH who did not author the study. “It’s reasonable for patients to make sure they’re getting the recommended amount of vitamin D, but I wouldn’t recommend high doses.”
Adults under 50 should aim for 600 IU of vitamin D daily. Those 50 and older should aim for 800 to 1,000 IU daily. The safe upper limit is 4,000 IU per day.
Curcumin
Curcumin is the main active compound in turmeric. It gives the spice its bright yellow colour and is known for its anti-inflammatory effects. “Curcumin has been shown as a potentially effective adjunctive treatment for psoriasis in both topical and oral formulations,” says Dr. Paul.
In the review, people who took curcumin along with their usual psoriasis treatment had lower levels of interleukin-22 (IL-22), a protein that drives inflammation in psoriasis. They also showed some symptom improvement. It’s thought that it may calm the immune signals that tell your body to make the pro-inflammatory proteins in the first place.
Curcumin in food and most supplements is generally safe (up to 4 grams of concentrated curcumin supplements per day). However, some highly concentrated forms may carry a risk of liver injury. Always talk with your doctor before starting a new supplement.
The Bottom Line
Research on supplements for psoriasis is still evolving. Of those studied, vitamin D and curcumin show the most potential—but neither replaces standard treatment. If you’re thinking about adding a supplement, talk with your dermatologist first. Together, you can decide what fits safely into your overall care plan.
Identification of sub-categories of the disease linked to gene expression also sheds light on why current treatments may fail.
A new major finding in how genes are linked to psoriasis could help offer tailored treatments for the common inflammatory condition, helping to treat the most stubborn and severe cases.
Psoriasis is a common inflammatory skin disease, with 1 in 50 people in the UK affected in some form. Despite its links to several long-term health conditions, such as heart disease and Type 2 diabetes, and the substantial impact severe psoriasis has on sufferers' quality of life, little is known about the causes of inflammatory and autoimmune diseases like it. This includes ailments like rheumatoid arthritis, lupus and Crohn's disease.
Because of this lack of understanding, current, high-cost treatment options such as biologics can fail for no visible reason - impacting patients and placing severe cost on the NHS.
By using advanced Machine Learning, researchers from King's, Newcastle University, and Queen Mary University of London, have identified several sub-types of the disease based on how someone's genes impact psoriasis severity. This classification will give clinicians a better idea of why current treatments may fail and open the door to more personalised ones.
"By using RNA sequencing and AI modelling, we can now categorise how genes affect the trajectory of psoriasis and group the disease into several sub-types as a prerequisite for better treatment - helping better deal with the most severe cases." - Dr David Watson
Dr David Watson, Lecturer in Artificial Intelligence and joint first author of the study said, "Diseases that present the same are often completely different. Breast cancer for example is not one, but a thousand different diseases all under the same label. To be able to develop targeted treatments you need to understand how all these different diseases work, or risk 'fat-fingered' interventions like chemotherapy which can have large side effects.
"Until now, we didn't have that with psoriasis. But by using RNA sequencing and AI modelling, we can now categorise how genes affect the trajectory of psoriasis and group the disease into several sub-types as a prerequisite for better treatment - helping better deal with the most severe cases."
Analysing 700 plus blood samples from over 140 patients with moderate to severe psoriasis over an extended period, the team mapped how genes interfaced both individually and in evolving networks with other biological factors, like BMI, to impact disease severity against common biologic treatments.
By figuring out how genes influence the path of one inflammatory disease, we hope to take this learning and apply it to a host of different diseases and see how they materialise in patients. If we can categorise the gene expression there too, we could potentially design personalised treatments for all these ailments which plague patients and cost our healthcare system millions."
Dr David Watson
They identified a nine-gene biomarker linked to psoriasis severity, along with specific genetic variants associated with more severe baseline disease. They also found a 14-gene signature connected to BMI in unaffected skin and to disease severity in affected skin displaying lesions.
In the future, the researchers hope to take they have learned from the gene expression involved in this inflammatory disease and apply it to others.
Dr Watson said "There are many immune mediated inflammatory diseases, like rheumatoid arthritis and Crohn's. And while they present differently, we know they are genetically linked - having one increases the risk of passing another to your kids.
"This is a complex world and by figuring out how genes influence the path of one inflammatory disease, we hope to take this learning and apply it to a host of different diseases and see how they materialise in patients. If we can categorise the gene expression there too, we could potentially design personalised treatments for all these ailments which plague patients and cost our healthcare system millions."
A hidden immune cell journey from skin to joints may explain psoriatic arthritis
Researchers have figured out how psoriasis can quietly turn into joint disease for some patients. Immune cells formed in inflamed skin can travel through the blood and reach the joints, where they sometimes trigger inflammation. The key difference lies in the joint’s ability to keep those cells in check. This insight could help doctors identify warning signs early and prevent lasting joint damage.
Roughly 20 to 30 percent of people with psoriasis eventually develop painful joint inflammation. This condition, known as psoriatic arthritis, can cause lasting damage to bones and joints if it is not treated. For years, doctors did not fully understand why psoriasis progressed to joint disease in some patients but not in others.
Researchers from the Department of Medicine 3 - Rheumatology and Immunology at Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), have now identified the specific immune cells responsible and uncovered how they move from the skin into the joints. Their findings point toward new ways to detect and prevent psoriatic arthritis before permanent joint damage occurs. The study has been published in Nature Immunology.
Scientists discovered that immune cells from psoriatic skin can migrate to the joints and ignite inflammation under the right conditions. Spotting these cells early could help stop psoriatic arthritis before it causes permanent damage. Credit: Shutterstock
How Immune Cells Travel From Skin to Joints
Psoriasis causes inflammation in the skin that leads to the formation of specialized immune precursor cells. These cells do not stay confined to the skin. According to the researchers, they can enter the bloodstream and later reach the joints.
"These cells can migrate from the skin to the bloodstream and from there to the joints," explains Dr. Simon Rauber, head of the working group at Department of Medicine 3. However, he notes that their presence alone does not automatically cause joint inflammation. "It is interesting that the mere migration of immune cells into the joint is not sufficient to trigger inflammation there."
Why Joint Inflammation Develops in Some Patients
What happens inside the joint itself plays a critical role. Once immune cells arrive, they interact with fibroblasts, which are connective tissue cells that normally help maintain balance and protect the joint. In people who go on to develop psoriatic arthritis, this protective response is weakened.
"The protective function of these connective tissue cells is usually considerably reduced in people who develop psoriatic arthritis," says Prof. Dr. Andreas Ramming, team leader and deputy head of department at Department of Medicine 3. "As a result, the inflammatory cells that enter the joint cannot be brought into check, and go on to trigger an inflammatory reaction in the joint." This breakdown helps explain why joint disease develops in some psoriasis patients but not others.
Early Warning Signs and New Prevention Strategies
The researchers also found that these migratory immune cells can be detected in the blood before joint inflammation begins. This discovery could make it possible to identify patients at higher risk earlier than ever before.
In the future, treatments may focus on targeting these immune cells before they reach the joints, stopping inflammation before it starts. Such approaches could help prevent psoriatic arthritis rather than treating damage after it has already occurred.
Research Funding and Support
The research is being funded by the German Research Foundation (DFG) within the framework of the CRC/TRR 369 - "DIONE: Degeneration of bone due to inflammation," by the European Research Council (ERC) as part of the project "Barrier Break," and by the Interdisciplinary Center for Clinical Research in Erlangen (IZKF) as part of the project "Tissue imprinting of skin-derived immune cells in psoriatic arthritis."
If you’re living with psoriasis, you already know that it’s far more than just a skin condition. The persistent redness, scaling, flaking, and itching can be physically uncomfortable and emotionally exhausting. These symptoms often affect more than your appearance: they can impact your sleep, self-esteem, social life, and even your mental health. For many people, managing psoriasis is a daily challenge that requires constant vigilance and, often, a frustrating cycle of trial and error with treatments.
Whether you’ve tried multiple topical creams, light therapies, or systemic medications, it’s not uncommon to feel stuck, especially when side effects become unbearable or treatments lose effectiveness over time. But there’s some exciting news for those who are still searching for better solutions.
In recent years, psoriasis research has made major strides. Scientists now understand far more about the immune pathways involved in the disease, and this has paved the way for a new generation of therapies that are more precise, effective, and better tolerated. From advanced oral medications and long-lasting injectables to innovative topical creams that go beyond basic symptom control, the treatment landscape is evolving fast.
In this article, we’ll explore some of the most promising treatments currently in development and those recently approved. You’ll get a closer look at how these therapies work, what makes them different, and why experts are feeling optimistic about the future of psoriasis care. Whether you’re newly diagnosed or have been living with psoriasis for years, there are real reasons to feel hopeful about what’s coming next.
Why Psoriasis Is So Complex
Before we explore the latest treatment options, it’s helpful to understand why psoriasis is often so difficult to manage and why there’s no one-size-fits-all solution.
At its core, psoriasis is a chronic autoimmune condition. That means the body’s own defence system, which is supposed to protect you from infections and harmful invaders, mistakenly attacks healthy skin cells instead. This triggers a rapid overproduction of skin cells, which causes them to accumulate on the skin’s surface far faster than normal. The result? Thick, scaly, inflamed patches that can itch, crack, and feel incredibly uncomfortable.
But what causes the immune system to go into overdrive in the first place? That’s where things get even more complex. Psoriasis is influenced by a variety of internal and external triggers, and these can differ significantly from person to person. Common factors that can spark or worsen psoriasis include:
Genetics: If someone in your immediate family has psoriasis, your risk of developing it increases. Certain genes have been linked to the condition, although not everyone with those genes will go on to develop symptoms.
Infections: Bacterial or viral infections, especially strep throat, can trigger flare-ups, particularly in children or those genetically predisposed.
Stress: Emotional and physical stress are well-known contributors. Stress can disrupt immune function and spark inflammation, setting off or aggravating symptoms.
Skin injuries: Even minor trauma like cuts, scrapes, sunburns, or insect bites can lead to new patches of psoriasis in a phenomenon known as the Koebner response.
Medications: Certain prescription drugs including beta-blockers, lithium, and some anti-malarials have been linked to psoriasis flares in susceptible individuals.
Because so many different factors are involved, managing psoriasis isn’t just about treating the skin, it’s about treating the underlying immune dysfunction. That’s why most effective treatments work on two levels:
Calming the immune system to reduce inflammation and prevent flare-ups.
Supporting skin healing by slowing cell growth, relieving symptoms, and restoring the skin barrier.
And to complicate things further, no two people with psoriasis are exactly alike. The severity of symptoms, the triggers, and the way your body responds to treatment can vary enormously. A cream or medication that works wonders for one person may offer little relief to another.
This complexity is one of the reasons why psoriasis research is so vital. It helps pave the way for more personalised, effective treatments and gives patients more options to find what works best for them.
What Makes New Treatments Different?
For years, people with moderate to severe psoriasis have relied on older therapies like traditional systemic drugs (such as methotrexate or cyclosporine) and high-potency topical steroids. While these treatments have helped many manage their symptoms, they also come with potential downsides. Long-term use can lead to issues such as liver toxicity, widespread immune suppression, or thinning and damage to the skin.
That’s where newer treatments are beginning to make a real difference. Current research is focused on precision medicine developing therapies that zero in on the specific immune pathways responsible for psoriasis, rather than affecting the immune system as a whole. These targeted approaches aim to interrupt the overactive immune signals without suppressing the body’s entire defence mechanism.
The result? Treatments that may offer better disease control with fewer systemic side effects, allowing patients to manage their psoriasis more effectively and with greater confidence in the long-term safety of their care.
Next-Generation Oral Medications
Oral treatments have traditionally included drugs like methotrexate or cyclosporine, which work by broadly dampening the immune system. Today’s research is aiming for more selective options.
TYK2 Inhibitors
One of the most anticipated new classes is the TYK2 inhibitors. TYK2 is an enzyme involved in inflammatory signalling. By blocking it, these drugs can reduce psoriasis activity without fully suppressing the immune system. Deucravacitinib is the first TYK2 inhibitor to show promising results in phase 3 trials.
In studies, it significantly improved skin clearance with a safety profile considered better than some older oral drugs.
Potential benefits:
Once-daily dosing
No need for injections
Lower risk of infections compared to broad immunosuppressants
This could be an important option for people who prefer tablets over biologics.
Targeted Injectable Biologics
Injectable biologics have transformed psoriasis treatment over the past 15 years.
Medications like adalimumab, ustekinumab, and secukinumab target specific cytokines molecules that fuel inflammation. The newest generation goes even further in precision.
IL-23 Inhibitors: IL-23 plays a critical role in psoriasis inflammation. New IL-23 inhibitors, including guselkumab and risankizumab, block this molecule more selectively than older biologics.
Why does this matter?
They’re highly effective in achieving near-complete skin clearance.
They generally have fewer side effects than TNF inhibitors.
They require infrequent dosing (every 8–12 weeks).
For many people, this means better results with less disruption to daily life.
IL-17 Inhibitors
Among the newer classes of biologic treatments, IL-17 inhibitors have emerged as a particularly effective option for many people with moderate to severe plaque psoriasis. Medications in this category such as ixekizumab (Taltz) and brodalumab (Siliq)work by blocking interleukin-17, a key inflammatory cytokine involved in the development of psoriatic plaques.
By targeting this specific part of the immune cascade, IL-17 inhibitors help disrupt the cycle of inflammation that causes rapid skin cell turnover and the build-up of thick, scaly patches.
These medications continue to show impressive long-term results in clinical studies, offering both durability and effectiveness. Some of the potential advantages include:
Rapid improvement: Many patients experience significant symptom relief within just a few weeks of starting treatment.
Effectiveness in hard-to-treat areas: IL-17 inhibitors have shown particularly strong results on areas that are often resistant to treatment, such as the scalp, nails, and palms.
Ongoing research is focused on optimising dosing schedules and further evaluating long-term safety, especially in real-world settings. So far, the data suggests that these medications can offer sustained control of psoriasis with a relatively favourable safety profile.
New Topical Treatments
Not everyone with psoriasis needs systemic drugs. For mild to moderate cases, topical treatments remain first-line therapy. Research is focusing on smarter creams and ointments that deliver results without the drawbacks of steroids.
PDE4 Inhibitors: PDE4 inhibitors, such as crisaborole (already used in eczema), are being adapted for psoriasis. They reduce inflammation by blocking the enzyme phosphodiesterase 4.
Benefits:
Steroid-free
Suitable for sensitive areas
Lower risk of skin thinning
Clinical trials are underway to confirm their role in plaque psoriasis.
Topical JAK Inhibitors
Janus kinase (JAK) inhibitors represent an exciting and relatively new approach to treating psoriasis especially in topical form. These medications work by blocking the activity of specific enzymes (JAKs) that play a key role in transmitting inflammatory signals within cells. By interrupting this process, JAK inhibitors can help reduce the immune-driven inflammation that fuels psoriasis symptoms.
What makes topical JAK inhibitors especially promising is their ability to target inflammation directly at the skin level. Because they’re applied as a cream or ointment, they act locally limiting systemic absorption and reducing the risk of broader side effects often associated with oral or injectable treatments.
Early clinical studies have shown that these topicals may be particularly effective for treating small, localised, and persistent plaques especially in patients who haven’t responded well to standard creams. They may also serve as a valuable alternative for individuals who require stronger topical therapy but are looking to avoid long-term use of corticosteroids, which can thin the skin over time.
Several topical JAK inhibitors are currently under investigation or awaiting regulatory approval, and dermatologists are optimistic about their role in filling the gap between mild and systemic treatment options.
Advances in Light Therapy
Phototherapy has been a cornerstone of psoriasis treatment for decades especially narrowband UVB therapy, which helps slow skin cell growth and reduce inflammation. While effective, traditional light therapy often requires patients to visit a clinic several times a week, which can be time-consuming and difficult to maintain over the long term.
Fortunately, researchers and device developers are now finding innovative ways to make light therapy safer, more convenient, and more patient-friendly.
Some of the most promising advances include:
Home-based phototherapy units: Newer at-home devices are designed with built-in timers, safety locks, and exposure controls to minimise the risk of overuse or UV damage. These portable units allow patients to continue treatment without frequent clinic visits, making it a practical solution for those with busy schedules or limited access to dermatology centres.
Targeted laser therapy: For people with isolated or stubborn plaques, targeted laser devices (such as excimer lasers) can deliver concentrated UVB light to affected areas without exposing surrounding healthy skin. This approach can be particularly helpful for areas like the elbows, knees, or scalp.
Combination treatments: Light therapy is increasingly being paired with topical medications, such as vitamin D analogues or retinoids. This dual approach may enhance effectiveness while potentially reducing the need for higher UV doses.
Together, these innovations are helping to broaden the appeal and practicality of phototherapy, especially for patients seeking non-drug alternatives or wishing to minimise systemic treatments. As these technologies continue to improve, more people with psoriasis may be able to benefit from light therapy in ways that are safer, more precise, and easier to stick with.
Emerging Areas: Microbiome and Gene Therapy
Looking further ahead, researchers are exploring novel strategies to treat psoriasis at its root.
Microbiome-Based Treatments
The skin and gut microbiomes communities of bacteria living in and on your body are increasingly recognised as important in psoriasis.
Future treatments may include:
Probiotic supplements to rebalance gut bacteria
Topical applications of beneficial microbes
Prebiotics that support healthy microbial diversity
Although these are mostly in early stages, they could offer new, low-risk options down the line.
Gene Therapy and RNA-Based Treatments
While most current psoriasis treatments focus on managing symptoms or calming the immune system, scientists are now exploring the possibility of going deeper right to the genetic level.
Emerging research in gene therapy and RNA-based treatments aims to address the root causes of psoriasis by altering how genes linked to the disease behave. Instead of suppressing inflammation after it starts, these therapies could one day prevent the abnormal immune response from happening in the first place.
One approach under investigation is gene editing, which involves modifying or disabling specific genes that play a role in psoriasis. Another is RNA interference (RNAi)a technique that uses small RNA molecules to block the production of inflammatory proteins at the cellular level. These treatments could be highly precise, affecting only the problematic immune signals while sparing healthy cells.
Right now, both gene therapy and RNAi are still in the early experimental stages and not yet available for clinical use in psoriasis. However, early studies in labs and animal models are showing promise.
While it may take several more years of research and testing, these innovations hold exciting long-term potential. In the future, they could offer people with psoriasis a chance at not just symptom control but lasting, disease-modifying treatment.
Lifestyle and Self-Care Still Matter
While cutting-edge medical treatments are transforming psoriasis care, it’s important not to overlook the impact of daily habits and lifestyle choices. Even with the best medications, how you care for your body on a day-to-day basis can make a significant difference in managing symptoms, reducing flare-ups, and improving overall skin health.
Dermatologists consistently emphasise the value of supportive self-care routines, which can complement clinical treatments and help keep psoriasis under control. Key recommendations include:
Moisturising regularly: Dry skin can worsen itching and make plaques more uncomfortable. Using moisturisers daily, especially after bathing, helps maintain the skin barrier and reduce irritation.
Avoiding common triggers: Smoking, heavy alcohol consumption, and high levels of stress are all known to provoke flare-ups in many individuals. Identifying and managing your personal triggers can be a powerful tool in reducing symptom severity.
Maintaining a healthy weight: Obesity has been linked to more severe psoriasis and reduced treatment response. Even modest weight loss can improve outcomes and reduce inflammation throughout the body.
Sticking with your treatment plan: It’s tempting to pause medication when your skin starts to clear, but consistency is key. Psoriasis is a chronic condition, and staying on track even during calm periods helps prevent flare-ups from returning.
By combining the latest medical advances with thoughtful, ongoing self-care, you give yourself the best chance of achieving long-term stability and healthier skin. It’s a team effort between your treatment plan, your dermatologist, and your daily choices.
What Should You Do Now?
If you’re struggling with psoriasis or thinking about changing treatments, don’t wait to talk to a specialist.
A dermatologist can help you:
Review the latest options that suit your type and severity of psoriasis
Discuss the pros and cons of each approach
Create a plan that fits your lifestyle and goals
The landscape of psoriasis care is evolving fast and you deserve to feel informed and empowered.
Final Thought: Relief Is Within Reach
Living with psoriasis can be frustrating, but it’s an exciting time in research. New therapies whether oral, injectable, or topical are offering better results with fewer side effects. and in the coming years, options will only continue to expand.
